Latest
Recommended
Published: Sun, January 08, 2017
Economy | By Melissa Porter

Alexion Pharmaceuticals, Inc. (ALXN) Rating Reiterated by Robert W. Baird

Alexion Pharmaceuticals, Inc. (ALXN) Rating Reiterated by Robert W. Baird

Looking over the last month situation it was ranked as "Buy" by 4 analysts. Pitcairn Co. raised its position in shares of Alexion Pharmaceuticals by 32.5% in the second quarter. FMR LLC now owns 18,745,795 shares of the biopharmaceutical company's stock valued at $2,188,759,000 after buying an additional 2,002,085 shares during the period.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares moved to $139.18 on Thursday.

In a Securities and Exchange Commission filing, Alexion said it continues to expect last year's sales to be between $3.05 billion and $3.1 billion, and adjusted earnings per share to be in the range of $4.50 to $4.65 a share. 3,547,952 shares of the company's stock were exchanged. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of Alexion Pharmaceuticals by 1.5% in the second quarter.

There are 7 hold ratings, 16 buy ratings on the stock. The Insider Ownership of the company now is 0.4 percent, and Institutional Ownership is 96.8 percent.

On 10/31/2016 Leonard Bell, Director, sold 1,300 with an average share price of $135.28 per share and the total transaction amounting to $175,864.00.

Alexion Pharmaceuticals, Inc. Gross Margin percentage stands at 91.6% while its Operating Margin for trailing twelve month is 21.6 percent and Profit margin (ttm) is 12.5 Percent. The stock's current distance from 20-Day Simple Moving Average (SMA20) is 14.46% where SMA50 and SMA200 are 13.5% and 6.16% respectively. (NASDAQ:ALXN) traded with the volume of 3.04 Million in the previous trading session. For the Current Quarter, 10 analysts are projecting the mean EPS to be $1.38/share. The firm had revenue of $799 million for the quarter, compared to analysts' expectations of $787.07 million. During the same quarter in the prior year, the business earned $1.16 earnings per share. Alexion Pharmaceuticals's revenue for the quarter was up 19.9% compared to the same quarter a year ago. Cowen and Company reissued a "buy" rating on shares of Alexion Pharmaceuticals in a research report on Thursday, September 22nd. The legal version of this report can be accessed at https://www.com-unik.info/2017/01/07/alexion-pharmaceuticals-inc-alxn-rating-reiterated-by-robert-w-baird.html. For the Q4 this year, the consensus current earnings per share trend estimates was for $1.26 while for one month ago was $1.27. Alexion Pharmaceuticals presently has a consensus rating of Buy and an average price target of $172.85.

According to Yahoo Finance, the price target for the company which analysts are aiming is 211.

Many research firms have provided their ratings on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)-5 analysts issued Strong buy for the stock, 10 analysts have given a Buy rating, 4 think it's a HOLD, 0 reported it as Underperform, while 0 analyst issued a Sell rating.

In related news, EVP Carsten Thiel sold 2,308 shares of the firm's stock in a transaction on Friday, December 9th. The stock was sold at an average price of $126.29, for a total transaction of $82,088.50. Following the sale, the executive vice president now directly owns 30,433 shares in the company, valued at $3,956,290.

Like this: